Stoke Therapeutics, Inc.
About Stoke Therapeutics, Inc.
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the bodys potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $184.4M
- Net income
- -$6.9M
- Total assets
- $418.4M
- Market cap
- $1.9B
- Operating margin
- -11.2%
- Net margin
- -3.7%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $184.4M
- Operating expenses
- $205.0M
- Operating income
- -$20.6M
- Income tax
- $0
- Net income
- -$6.9M
- EPS (basic)
- $-0.12
- EPS (diluted)
- $-0.12
Balance sheet
- Total assets
- $418.4M
- Current assets
- $305.7M
- Total liabilities
- $66.0M
- Current liabilities
- $57.9M
- Shareholders’ equity
- $352.5M
Cash flow
- Operating cash flow
- $45.6M
- Investing cash flow
- -$186.8M
- Financing cash flow
- $97.4M
- Net cash flow
- -$43.8M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $1.9B
- EPS (diluted)
- $-0.12
- Shares outstanding
- 64.5M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jun 19, 2019
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $6.9M in FY2025.
- Trading 24% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Stoke Therapeutics, Inc..
Write a review
News about Stoke Therapeutics, Inc.
News & sentiment via Polygon.io
